Hikma publishes its 2024 Sustainability Report reinforcing commitment to global access to medicines
London, 30 June 2025 – Hikma Pharmaceuticals PLC (Hikma), the multinational pharmaceutical company, today announces the publication of its 2024 Sustainability Report, showcasing the Company's unwavering commitment to improving access to high-quality medicines globally.
The report underscores Hikma's purpose-driven approach to sustainability, with medicine accessibility serving as the cornerstone of its environmental, social, and governance (ESG) strategy.
"Access to medicines remains at the heart of everything we do at Hikma " said Tim Brooks, VP Sustainability. "This sustainability report highlights our belief that providing high-quality medicines is not just our business—it's our responsibility to our people, customers, healthcare professionals, patients and the communities we serve around the world. This year, we have further reinforced access to medicine as the core of our sustainability strategy by leveraging our strong manufacturing presence and working with stakeholders across the healthcare ecosystem.
He added, “This key objective is supported by our commitment to our people, our planet, and our suppliers. Additionally, we have introduced metrics for each of these areas to demonstrate our performance and ensure sustainability remains embedded throughout our corporate strategy.”
The report also details Hikma's progress in advancing health and wellbeing by empowering its people, protecting the environment, and operating transparently and ethically.
The full sustainability report is available at https://www.hikma.com/responsibility/sustainability-reports/